Glenmark Shares

• 

  Glenmark Life Sciences Makes A Listless Debut; Lists At 4% Premium

  The shares of Glenmark Life Sciences opened at Rs 751 on the BSE, a premium of 4 per cent compared to the issue price of Rs 720.

• 

  Glenmark Life Sciences To Debut Tomorrow. Here's What To Expect

  Glenmark Life Sciences IPO comprised a fresh issue of Rs 1,060 crore and an offer-for-sale of Rs 453.60 crore by the promoters

• 

  Glenmark Life Sciences IPO Subscribed Nearly 45 Times On Final Day Of Issue

  Glenmark Life Sciences' share sale via initial public offering (IPO) was subscribed by 44.17 times on Thursday, July 29- the third and final day of its issue.

• 

  Glenmark Life Sciences IPO Subscribed Nearly 6 Times On Second Day Of Issue

  Glenmark Life Sciences' share sale via initial public offering (IPO) was oversubscribed by 5.78 times on Wednesday, July 28 - the second day of its issue.

• 

  Glenmark Life Sciences IPO Fully Subscribed Within Hours Of Opening

  Glenmark Life Sciences' Rs 1,513 crore IPO comprises of fresh issue of Rs 1,060 crore and an offer for sale of Rs 453.60.

• 

  Glenmark Life Sciences IPO Opens Today

  Glenmark Life Sciences IPO, which will be open for three days until July 29, will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares

• 

  Glenmark Life Sciences IPO To Open Tomorrow. Should You Subscribe?

  Glenmark Life Sciences' IPO will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares by Glenmark Pharmaceuticals

• 

  Glenmark Life Sciences IPO To Open On July 27. Here's All You Need To Know

  Glenmark Life Sciences' IPO will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares by Glenmark Pharmaceuticals

• 

  Glenmark Arm Files Papers For Rs 1,160 Crore Glenmark Life Sciences' IPO

  The IPO comprises a fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73.05 lakh equity shares by Glenmark Pharmaceuticals.

• 

  Glenmark Life Sciences Files IPO Papers With Sebi

  Glenmark Life Sciences IPO: The offer will comprise a fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73,05,245 equity shares of Rs 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals

• 

  Glenmark Pharma Gets Regulatory Nod For Tacrolimus Capsules; Stock Gains Nearly 2%

  Glenmark Pharma received final approval from USFDA for Tacrolimus capsules, which are used as immunosuppressants to prevent human immune system from rejecting liver, kidney and heart transplants.

• 

  Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version

  Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.

• 

  Glenmark Shares Surge Over 35% On Regulatory Approval For COVID-19 Drug

  Favipiravir being manufactured by Glenmark will be marketed by the name of Fabiflu and will be available in strength of 200 milligrams.

• 

  Glenmark To Conduct Clinical Trials For Potential COVID-19 Drug; Shares Surge

  Glemark said the approval made it the first pharmaceutical company in India to be given the go-ahead to start trials on COVID-19 patients.

• 

  Glenmark Pharma To Conduct Trials For Potential COVID-19 Drug, Shares Jump

  Glenmark Pharmaceuticals, which rose as much as 8.9 per cent to Rs 359, traded up 5.9 per cent at 9:37 am.